Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of SAR125844 in Pretreated Advanced NSCLC With MET Gene Amplification
2014-005696-93Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SAR125844 in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Primary endpoint: Objective response rate (ORR). Started Feb 2015; status: terminated.
02
Drugs
SAR125844
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005696-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005696-93.